SMAD4 Genetic Alterations Predict a Worse Prognosis in Patients With Pancreatic Ductal Adenocarcinoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Pancreas

• Publication date

  2012-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/MPA.0b013e318247d6afPMID 22504380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TNM Classification of Malignant Tumors, 7th edition

  2010cited by this paper
• SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer

  2009cited by this paper
• Inactivation of SMAD4 Tumor Suppressor Gene During Gastric Carcinoma Progression

  2007cited by this paper
• Missense Mutations of MADH4

  2004cited by this paper
• Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction

  2004cited by this paper
• Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma.

  2003influential reference
• Tumor-Suppressing Pathways in Cystic Pancreatic Tumors

  2003cited by this paper
• K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis.

  2002cited by this paper
• DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.

  2002cited by this paper
• Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis

  2001cited by this paper
• Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct.

  2001influential reference
• Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway.

  2000cited by this paper
• Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer

  1999cited by this paper
• Tumor-suppressor genes in pancreatic cancer.

  1998cited by this paper
• Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases.

  1998cited by this paper
• TNM classification of malignant tumors, fifth edition (1997)

  1997cited by this paper
• DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1

  1996cited by this paper
• PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA.

  1991cited by this paper
• Fast and sensitive silver staining of DNA in polyacrylamide gels.

  1991cited by this paper
• The American Joint Committee on Cancer.

  1984cited by this paper

• A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17)

  2024cites this paper
• An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment

  2024cites this paper
• Exploiting the molecular subtypes and genetic landscape in pancreatic cancer: the quest to find effective drugs

  2023cites this paper
• Current Pathology Model of Pancreatic Cancer

  2022cites this paper
• The Role of SMAD4 Inactivation in Epithelial–Mesenchymal Plasticity of Pancreatic Ductal Adenocarcinoma: The Missing Link?

  2022cites this paper
• Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head

  2022cites this paper
• Molecular alterations in pancreatic tumors

  2021cites this paper
• An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression

  2021cites this paper
• Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy

  2021cites this paper
• Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

  2021cites this paper
• Correction to: Imaging phenotype using 18F-fluorodeoxyglucose positron emission tomography-based radiomics and genetic alterations of pancreatic ductal adenocarcinoma

  2020cites this paper
• A Nomogram for Individual Prediction of Poor Prognosis After Radical Surgery in Patients with Primary Pancreatic Duct Adenocarcinoma

  2020cites this paper
• Imaging phenotype using 18F-fluorodeoxyglucose positron emission tomography–based radiomics and genetic alterations of pancreatic ductal adenocarcinoma

  2020cites this paper
• Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?

  2020cites this paper
• Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?

  2020cites this paper
• Circadian Dysregulation of the TGFb/SMAD4 Pathway Modulates Metastatic Properties and Cell Fate Decisions in Pancreatic Cancer Cells

  2020cites this paper
• Molecular Biology of Biliopancreatic Lesions

  2020cites this paper
• Circadian Dysregulation of the TGFβ/SMAD4 Pathway Modulates Metastatic Properties and Cell Fate Decisions in Pancreatic Cancer Cells

  2020cites this paper
• Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers

  2020cites this paper
• Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma

  2020cites this paper
• HEATR1 Deficiency Promotes Chemoresistance via Upregulating ZNF185 and Downregulating SMAD4 in Pancreatic Cancer

  2020cites this paper
• Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?

  2020cites this paper
• Cancer-Associated Fibroblasts’ Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma

  2019cites this paper
• Intracellular pH dynamics and charge-changing somatic mutations in cancer

  2019cites this paper
• CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma

  2019cites this paper
• SMAD4 Y353C promotes the progression of PDAC

  2019cites this paper
• Clinicopathological Significance of SMAD4 Expression in Breast Cancer

  2019cites this paper
• Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma.

  2019cites this paper
• Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation

  2018cites this paper
• The role of TGF-β/SMAD4 signaling in cancer

  2018cites this paper
• Team work and cytopathology molecular diagnosis of solid pancreatic lesions

  2017cites this paper
• The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy

  2017cites this paper
• Endoscopic Ultrasonography with Fine-needle Aspiration: New Techniques for Interpretation of Endoscopic Ultrasonography Cytology and Histology Specimens.

  2017cites this paper
• KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

  2017cites this paper
• Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes

  2017cites this paper
• Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer

  2016cites this paper
• Smad4 inhibits cell migration via suppression of JNK activity in human pancreatic carcinoma PANC-1 cells.

  2016cites this paper
• Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis

  2015cites this paper
• Dissecting the Epidemiology of Pancreatic Adenocarcinoma

  2015cites this paper
• Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors

  2015cites this paper
• MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4

  2015cites this paper
• Ductal adenocarcinoma of the pancreas usually retained SMAD4 and p53 protein status as well as expression of epithelial-to-mesenchymal transition markers and cell cycle regulators at the stage of liver metastasis.

  2014cites this paper
• SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells

  2014cites this paper
• Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

  2014cites this paper
• The clinical utility of biomarkers in the management of pancreatic adenocarcinoma.

  2014cites this paper
• SMAD4 and its role in pancreatic cancer

  2014cites this paper
• Loss of SMAD4 staining in pre‐operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer

  2014cites this paper
• Identification of Potential Biomarkers in PDAC

  2014cites this paper
• TOPIC HIGHLIGHT

  2014cites this paper
• [Will molecular diagnostics become established in pancreatic pathology?].

  2013cites this paper
• Personalizing pancreatic cancer medicine: what are the challenges?

  2013cites this paper
• Findet die molekulare Diagnostik Einzug in die Pankreaspathologie?

  2013cites this paper
• Triterpenes from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7

  2013cites this paper